All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
All-trans retinoic acid (ATRA) can induce complete remission (CR) in most patients with acute promyelocytic leukemia (APL) through in vivo differentiation of APL-blasts. However, it cannot eliminate the leukemic clone and must be used in combination with anthracycline-based chemotherapy. Experience accumulated over the last 10 years has clearly shown that the combination of ATRA and chemotherapy gave better survival than chemotherapy alone in newly diagnosed APL because of fewer relapses and a slightly higher CR rate. It is also strongly suggested that maintenance treatment with ATRA, and possibly with low-dose chemotherapy, can further reduce the incidence of relapse. Overall, more than 90% of patients with newly diagnosed APL can achieved CR, and about 75% can be cured by the combination of ATRA and chemotherapy. ATRA syndrome remains the major side effect of ATRA treatment, which should be prevented by addition of chemotherapy and/or dexamethasone in case of increasing white blood cell (WBC) counts. Current issues in the treatment of newly diagnosed APL include the role of early addition of chemotherapy to ATRA, whether or not ara-C is useful in combination with anthracycline, and a possible interest of arsenic trioxide during consolidation in patients remaining at relatively high risk of relapse.
Fenaux
P
P
Service des Maladies du Sang, CHU Lille, and the Institut d'Hématologie, H pital Saint Louis, Paris, France. pfenaux@chru-lille.fr
Chomienne
C
C
Degos
L
L
D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D014212:Tretinoin